Kancera AB (publ) reports that 63 subjects have been recruited to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, which exceeds the initial objective of 60 study subjects in total. Kancera has previously announced...
Read MoreKancera AB (publ) today announces that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer and entered into an agreement with the Nordic Society of Gynaecological Oncology...
Read MoreThis is a translation of the interim report published in Swedish at October 26, 2022
Read MoreKancera AB (publ) reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. Preclinical studies of KAN571 in MCL cell lines show that KAN571 effectively...
Read MoreKancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).
Read More